THEPCA (V1)
Research type
Research Study
Full title
Timing of HDR brachytherapy with EBRT in intermediate and high risk localised prostate cancer patients and its effects on toxicity and Quality of life - randomised controlled feasibility trial.
IRAS ID
140231
Contact name
Imtiaz Ahmed
Contact email
Sponsor organisation
Southend University Hospital NHS Foundation Trust
Research summary
Prostate Cancer is the most common cancer in males in UK affecting around 105 cases for every 100,000 men. The role of radiotherapy in management of prostate cancer significantly changed over the last few decades with the developments in Brachytherapy, External Beam Radiotherapy (EBRT), Intensity modulated Radiotherapy (IMRT) and Image guided Radiotherapy (IGRT). One of the challenging factors of Radiotherapy treatment of localised prostate cancer is acute and late Genitourinary and Gastrointestinal toxicities. There are several studies and case series published in literature assessing the toxicities developed during EBRT and Brachytherapy treatment for prostate cancer.
Radiotherapy with a curative intention is needed to treat prostate cancer and combination of External Beam Radiotherapy and High Dose Rate Brachytherapy is well recognised mode of treatment. However, it is not very clear from the evidence which sequence of the above treatments (i.e. Brachytherapy either before or after the External Beam Radiotherapy) would result in least side effects. The study is going to look at the timing of High dose rate Prostate Brachytherapy with External beam Radiotherapy. Regular assessments will be made of the symptoms and side-effects occurring during and after the treatment. We will also look at the outcome of the treatment.
REC name
London - Stanmore Research Ethics Committee
REC reference
14/LO/1662
Date of REC Opinion
22 Sep 2014
REC opinion
Further Information Favourable Opinion